Baker Avenue Asset Management, LP Gilead Sciences, Inc. Transaction History

Baker Avenue Asset Management, LP

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	SELL	$73.94 - $80.67 $10,721 - $11,697	-145 Reduced 19.52%	598 $44,000
Q2 2023 Aug 11, 2023	BUY	$76.01 - $86.7 $10,717 - $12,224	141 Added 23.42%	743 $57,000
Q1 2023 May 15, 2023	BUY	$77.31 - $88.08 $24,739 - $28,185	320 Added 113.48%	602 $49,000
Q4 2022 Feb 13, 2023	BUY	$62.32 - $89.47 $17,574 - $25,230	282 New	282 $24,000
Q2 2022 Aug 03, 2022	SELL	$57.72 - $65.01 $277,056 - $312,048	-4,800 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$57.92 - $72.58 $52,185 - $65,394	901 Added 23.11%	4,800 $285,000
Q4 2021 Feb 11, 2022	BUY	$64.88 - $73.64 $25,887 - $29,382	399 Added 11.4%	3,899 $283,000
Q3 2021 Nov 15, 2021	BUY	$67.69 - $73.03 $236,915 - $255,605	3,500 New	3,500 $244,000
Q4 2017 Feb 14, 2018	SELL	$71.15 - $83.52 $184,278 - $216,316	-2,590 Closed	0 $0
Q3 2017 Nov 14, 2017	SELL	$72.11 - $85.47 $18,027 - $21,367	-250 Reduced 8.8%	2,590 $210,000
Q2 2017 Aug 11, 2017	BUY	N/A	2,840	2,840 $201,000

1,927

994M

10.5M

9.75M

Ticker GILD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,253,369,984
Market Cap $116B
Description
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...

Get notified when there are updates to the investment portfolio of Baker Avenue Asset Management, LP, based on Form 13F filings with the SEC.

Stay updated on Baker Avenue Asset Management, LP with notifications on news.